Published in J Infect Dis on January 01, 2011
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. J Infect Dis (2011) 1.64
Towards the eradication of HPV infection through universal specific vaccination. BMC Public Health (2013) 1.01
Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev (2012) 0.95
Correlation between HPV sperm infection and male infertility. Asian J Androl (2013) 0.92
Human papillomavirus genital infections among men, China, 2007-2009. Emerg Infect Dis (2013) 0.91
Circumcision and acquisition of human papillomavirus infection in young men. Sex Transm Dis (2011) 0.87
Does Male Circumcision Protect against Sexually Transmitted Infections? Arguments and Meta-Analyses to the Contrary Fail to Withstand Scrutiny. ISRN Urol (2014) 0.86
Penile cancer disparities in Puerto Rican men as compared to the United States population. Int Braz J Urol (2013) 0.84
High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial. J Acquir Immune Defic Syndr (2015) 0.81
High-risk human papillomavirus prevalence is associated with HIV infection among heterosexual men in Rakai, Uganda. Sex Transm Infect (2012) 0.79
Sexually transmitted infections and male circumcision: a systematic review and meta-analysis. ISRN Urol (2013) 0.78
Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs. World J Urol (2014) 0.78
Expressed prostate secretions in the study of human papillomavirus epidemiology in the male. PLoS One (2013) 0.78
Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial. J Infect (2015) 0.77
Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia. Clin Vaccine Immunol (2015) 0.77
Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis (2017) 0.75
Critical evaluation of unscientific arguments disparaging affirmative infant male circumcision policy. World J Clin Pediatr (2016) 0.75
Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study. BMC Public Health (2016) 0.75
Characteristics of human papillomaviruses infection in men with genital warts in Shanghai. Oncotarget (2016) 0.75
HPV SEROSTATUS PRE- AND POST-VACCINATION IN A RANDOMIZED PHASE II PREPAREDNESS TRIAL AMONG YOUNG WESTERN CAPE, SOUTH AFRICAN WOMEN: THE EVRI TRIAL. Papillomavirus Res (2017) 0.75
Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study. Emerg Microbes Infect (2016) 0.75
Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic. Sex Transm Infect (2012) 0.75
Comparison of the natural history of genital HPV infection among men by country: Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med (2007) 15.40
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
Chapter 2: The burden of HPV-related cancers. Vaccine (2006) 7.70
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev (2005) 2.86
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis (2008) 2.56
Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis (2000) 2.16
Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine (2008) 2.13
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer (2009) 2.01
Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis (2009) 1.80
Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev (2005) 1.71
Prevalence and risk factors of genital human papillomavirus (HPV) infections in healthy males: a study on Finnish conscripts. Sex Transm Dis (1994) 1.61
Risk factors for anogenital human papillomavirus infection in men. J Infect Dis (2007) 1.59
Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis (2008) 1.55
Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J Natl Cancer Inst Monogr (1998) 1.51
Male influences on cervical cancer risk. Am J Epidemiol (1986) 1.46
Human papillomaviruses and anogenital cancers. N Engl J Med (1997) 1.44
Asymptomatic penile HPV infection: a prospective study. Int J STD AIDS (2000) 1.23
Prevalence of human papillomavirus infections among heterosexual men and women with multiple sexual partners. J Med Virol (1992) 1.12
Study comparing human papillomavirus (HPV) real-time multiplex PCR and Hybrid Capture II INNO-LiPA v2 HPV genotyping PCR assays. J Clin Microbiol (2009) 1.00
Strategies for HPV prevention. Virus Res (2002) 0.93
Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev (2000) 0.85
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med (2007) 12.17
Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med (2011) 11.09
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst (2005) 5.29
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
Loss of vaccine-induced immunity to varicella over time. N Engl J Med (2007) 4.55
Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2006) 4.33
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19
[A man in his 30s with urethral discharge and dysuria]. Tidsskr Nor Laegeforen (2014) 3.67
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis (2012) 3.19
IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood (2009) 3.14
Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ (2011) 2.95
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis (2009) 2.92
Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer (2009) 2.90
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med (2012) 2.72
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine (2011) 2.43
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer (2007) 2.37
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 2.33
Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis (2002) 2.22
Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus-associated anal intraepithelial neoplasia in men who have sex with men. Ann Intern Med (2008) 2.22
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis (2004) 2.21
Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med (2003) 2.21
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst (2011) 2.18
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology (2004) 2.16
Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis (2012) 2.16
The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis (2007) 2.14
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13
Anal human papillomavirus infection is associated with HIV acquisition in men who have sex with men. AIDS (2009) 2.12
A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev (2008) 2.10
Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis (2010) 2.10
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09